



333 North Smith Avenue
St. Paul, MN 55102
651-241-8000

2023
United Hospital
Antimicrobial Susceptibilities
of Major Pathogens

- The intent of this document is to provide a preliminary guide to susceptibilities. This information should be used together with the specific susceptibility results of the isolated organism and guidelines from current publications. This report summarizes routinely tested antibiotics. Actual patient reports may selectively exclude some results
- Results are from inpatients only and include only one isolate per patient.
- Isolates collected from Emergency Department visits are included in the inpatient antibiogram.
- MRSA and VRE surveillance culture isolates are not included.
- All intermediate (I) interpretations are included in the resistant category.
- All organisms identified are held for a period of 7 days after the final results have been reported in case further testing is requested. Blood culture isolates are held for 1 month. Testing of additional antimicrobials is available upon request.
- Additional guidance can be found on the [Allina Health Antibiotic Stewardship Program](#) web page.

For further information, contact:

Brenda Katz, MD, Pathologist,
Brenda.Katz@allina.com, 612-863-4708

UNITED HOSPITAL-2023 ANTIMICROBIAL SUSCEPTIBILITIES

GRAM NEGATIVE BACILLI	ISOLATES	ANTIMICROBIALS														
		AMPICILLIN	AMPICILLIN/SULBACTAM	CEFZOLIN-UC *	CEFEPIME	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	LEVOFLOXACIN	MEROPENEM	NITROFURANTOIN	PIPERACILLIN/TAZO	TOBRAMYCIN	TRIMETHOPRIM/SULFA	
<i>Citrobacter</i> species (all combined)	92				98	85	83	95	97	93	100	91	88	98	97	
<i>Enterobacter</i> species (all combined)	159				96	83	81	93	97	93	100	60	82	97	94	
<i>Escherichia coli</i>	1237	54	64	87	92	91	91	78	91	74	99	96	95	91	76	
<i>Klebsiella aerogenes</i> (formerly <i>Ent. aerogenes</i>)	55				100	81	81	98	100	96	96	16	77	100	100	
<i>Klebsiella oxytoca</i>	97		63		100	100	95	97	100	97	100	89	94	100	95	
<i>Klebsiella pneumoniae</i>	272		80	92	93	93	92	90	95	85	99	34	93	94	90	
<i>Klebsiella variicola</i>	30		100		100	100	100	100	100	96	100		100	100	100	
<i>Morganella morganii</i>	47		8		97	91	95	87	89	87	100		100	95	85	
<i>Proteus mirabilis</i>	177	84	92	95	97	97	97	82	96	82	100		98	95	84	
<i>Pseudomonas aeruginosa</i>	272				93	92		89	95	81	91		87	99		
<i>Stenotrophomonas maltophilia</i>	38					47				86	33				94	

* Cefazolin-UC; the % susceptible can only be ascertained on isolates of *E.coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis* from uncomplicated UTIs. The cefazolin threshold for susceptible is <= 2 µg/ml for all other sources and Enterobacterales. The lowest dilution for cefazolin on the Allina FDA cleared automated platform is 4 µg/ml, thus no susceptible results can be determined by this method.

>90% Susceptible
61-89% Susceptible
0-60% Susceptible

GRAM POSITIVE COCCI	ISOLATES	ANTIMICROBIALS																					
		AMPICILLIN	AZITHROMYCIN	CEFZOLIN	CEFTRIAXONE	CEFTRIAXONE-MENINGITIS 2	CEFTRIAXONE-NONMENINGITIS 3	CLARITHROMYCIN	CLINDAMYCIN	DAPTOMYCIN 4	DOXYCYCLINE	ERYTHROMYCIN	GENTAMICIN 5	LEVOFLOXACIN	LINEZOLID	NITROFURANTOIN U	OXACILLIN	PENICILLIN	PENICILLIN-IV-MENINGITIS 6	PENICILLIN-IV-NONMENINGITIS 7	RIFAMPIN 8	TRIMETHOPRIM/SULFA	VANCOMYCIN
<i>Enterococcus faecalis</i>	469	99							69				87 ^U	100	98		98						98
<i>Enterococcus faecium</i>	84	16							90 ¹				17 ^U	98	32		17						30
<i>Staphylococcus aureus</i>	682		68					77	100	97	55	99	75	100	98	68					99	92	100
<i>Staphylococcus Coag Negative</i>	156		44					57	100	93	39	94	75	100	100	44					98	71	100
<i>Staphylococcus lugdunensis</i>	58		93					79	100	100	77	100	100	100		93					100	100	100
<i>Strep. agalactiae</i> (Strep Group B)	68	100		100				50			35		95	100		100							100
<i>Strep. dysgalactiae</i>	33	100		100				72			69		93	100		100							100
<i>Strep. pneumoniae</i> **	35		82		94	100	82									85	100	85			88	100	
<i>Strep. pyogenes</i> (Beta Strep group A)	50	100		100				86			86		97	100		100							100

^u Reported on urine isolates only.

¹ Daptomycin does not have recognized breakpoints for *E. faecium*. Susceptibilities reported in this antibiogram are based on the susceptible dose dependent (SDD) MIC ≤ 4 $\mu\text{g/mL}$ using an 8-12 mg/kg daily regimen. Infectious Disease consultation is recommended prior to utilizing daptomycin to cover *E. faecium*.

² Ceftriaxone - IV meningitis susceptible MIC ≤ 0.5 $\mu\text{g/mL}$.

³ Ceftriaxone - IV non-meningitis susceptible MIC ≤ 1 $\mu\text{g/mL}$.

⁴ Daptomycin not reported on isolates from respiratory tract.

⁵ Gentamicin should not be used as monotherapy for gram positive infections.

⁶ Penicillin - Oral and IV meningitis susceptible MIC ≤ 0.06 $\mu\text{g/mL}$

⁷ Penicillin - IV nonmeningitis susceptible MIC ≤ 2 $\mu\text{g/mL}$.

⁸ Rifampin should not be used alone for antimicrobial therapy.

** *S.pneumoniae* isolate distribution by specimen type; 42% blood, 39% respiratory, 0% spinal fluid, 18% other specimen types.

Links to Related Content

[Allina Health Laboratory](#)

[Organism Groupings of Routinely Test Antimicrobials at Allina Health Laboratory](#)

[Allina Health Antimicrobial Susceptibility Data](#)

[2024 Allina Health Antimicrobial Costs](#)

[Pharmacy Services](#)

[Antimicrobial Stewardship](#)